Efficacy of telmisartan and enalapril in patients with diabetic nephropathy

Abstract

Introduction: Diabetic nephropathy is characterized by hypertension and persistent proteinuria and is the leading cause of end stage renal disease (ESRD). The comparison of Telmisartan and Enalapril was designed to assess and compare the efficacies of both drugs in diabetic nephropathy patients.

Material and methods: All age groups of patients diagnosed with diabetic nephropathy are included in our study.

Results: 112 patients were recruited in the study. Patients taking Telmisartan and Enalapril once daily completed the study. There was a significant reduction in urine albumin, urine creatinine, urine albumin/creatinine ratio (UACR), serum creatinine, Blood pressure, Fasting blood sugar, Post lunch blood sugar, HbA1C, Total cholesterol, low density lipoprotein, very low density lipoprotein, high density lipoprotein and triglycerides.

Conclusion: Both Telmisartan and Enalapril were efficacious in diabetic nephropathy patients, but Enalapril showed more Reno protection than Telmisartan in this study.

Keywords: diabetic nephropathy, ESRD, telmisartan, enalapril, proteinuria

Background and aim

Diabetes mellitus is a metabolic complex disorder characterised by hyperglycaemia and glucose intolerance as their hallmark due to insulin deficiency or impaired effectiveness of insulin action.1 Diabetic nephropathy is one of the potential micro vascular complications in diabetic patients. It is the leading cause of End stage renal disease (ESRD). Diabetic kidney disease refers to chronic kidney disease (CKD) presumed to be caused by diabetes.2 Diabetic nephropathy is screened for persistent abnormal urine albumin excretion and by decreased glomerular filtration rate (GFR). Albuminuria has been divided into micro albuminuria (urine albumin creatinine ratio (UACR) 30-300 mg/dl) and macro albuminuria (UACR more than 300mg/dl). Serum creatinine derives estimates of GFR and diabetic kidney disease.1

Diabetic kidney disease can be detected by screening for persistent abnormal urine albumin excretion and by determining the estimated glomerular filtration rate. The main evidence based strategies for preventing or delaying loss of kidney function in diabetic patients include blood pressure control, blockade of renin-angiotensin system, and glycemic control. Controlling these factors and reducing proteinuria are now the main focus of diabetic kidney disease management. Through a multidisciplinary approach of implementing guidelines and timely referral, care of the diabetic kidney disease patient can be improved. The key is preventing and slowing the progression of this complication, to keep the other shoe from dropping.4,5

The aim of the study is to assess and compare the efficacy of Telmisartan and Enalapril in diabetic nephropathic patients. Angiotensin converting enzyme inhibitors and angiotensin receptor blocker have renal protection effects in diabetic patients. Enalapril, Angiotensin-converting–enzyme (ACE) inhibitors, which competitively block the renin–angiotensin system, decrease glomerular capillary pressure and prevent the progression of microalbuminuria to overt proteinuria.6

The side effects of enalapril are Edema, Dry cough, Dizziness, Hypertension, Syncope. Enalapril is contraindicated in pregnancy and breast feeding. Telmisartan is an angiotensin receptor antagonist possessing selective, and insurmountable inhibitory activity specific to the angiotensin II type 1 (AT1) Receptor.7 side effects are Tachycardia, Bradycardia, Hypotension, Edema and Allergic reactions. Telmisartan is contraindicated during pregnancy, in bilateral renal artery stenosis in which it can cause renal failure.

Literature

(Table 1).8-11

| Author         | Year | Study                                      | Conclusion                                                                 |
|----------------|------|--------------------------------------------|---------------------------------------------------------------------------|
| Roland et al.  | 2013 | Telmisartan in incipient and overt diabetic renal disease. | The Effect of telmisartan on kidney function support its use in patients with microalbuminuria or overt diabetic nephropathy. |
| Bhansali et al.| 2010 | Antalbumineric efficacy of ACE inhibitors and ARB’s in type 1 DM with nephropathy. | Dual blockade with ramipril enhanced with antalbumineric effect of telmisartan and reduced in blood pressure. |
| Anthony et al. | 2004 | ARB’S versus ACE inhibitors in type 2 DM and nephropathy. | Telmisartan is not inferior to enalapril in providing long term reno protection in persons with type 2 diabetes mellitus. |
| Johnsen et al. | 1992 | Renal protective effect of enalapril in diabetic nephropathy. | Treatment with enalapril can reduce the rate of decline in kidney function in patients with diabetic nephropathy. |

The Effect of telmisartan on kidney function support its use in patients with microalbuminuria or overt diabetic nephropathy.
Materials and methods

It is a prospective and observational research done in “SRI BHADRAKALI DIABETIC CLINIC” Naimnagar, Hanamakonda and Rakshith Multispeciality Hospital, Kakaji Colony, Warangal, Telangana, India. Patients were explained about the study & informed consent forms were seeked by explaining them in their local language. Institutional Human Ethical Committee Endorsement was obtained after submission of protocol and IHEC NO. is MGM/VCOP/ PHARMV/V/011/2018.

Inclusion criteria

a. Patients with diabetes treated by diet or/and oral hypoglycaemic agents or insulin.

b. Patients were required to have glycyslated haemoglobin (HbA1C).

c. Patients who have mild to moderate hypertension.

Exclusion criteria

a. Any clinical neurological disorder, medical or psychiatric conditions that would interfere with the patient’s ability to participate in the study.

b. History of compound abuse or dependence in the past year except nicotine and caffeine.

c. Pregnant or breast feeding women or any psychological conditions that might compromise participation in the study.

d. Patients with renal dysfunction not due to diabetes, a single kidney or known renal artery stenosis, congestive heart failure.

Study design

It is a prospective, observational, comparative study design, and the patients who are taking Telmisartan and Enalapril were included.

Clinical response assessment

The efficacy of Telmisartan and Enalapril was assessed by measuring the change in urine micro albuminuria, serum creatinine, Blood pressure, fasting blood sugar, post lunch blood sugar, HbA,C, Total cholesterol, low density lipoprotein, very low density lipoprotein, high density lipoprotein and triglycerides after 12 weeks of treatment. Primary end point was change in urine albuminuria, urine creatinine, urine albumin/creatinine ratio (UACR) and serum creatinine. Secondary end point was change in blood pressure, fasting blood sugar, post lunch blood sugar, HbA,C, total cholesterol, high density lipoprotein, very low density lipoprotein, low density lipoprotein, and triglycerides were measured at 12 weeks compared to the baseline levels.

Statistical analysis

All the parameters were expressed as mean±SD was performed by using the MS-EXCEL sheet 2013. All the parameters were obtained at baseline at the end of study.

Results

(Figures 1–15).

Discussion

Comparision of efficacy of Telmisartan and Enalapril was done in patients with diabetic nephropathy. The following glycemic parametres: Blood pressure, systolic blood pressure, diastolic blood sugar, post lunch blood sugar, HbA,C, micro albuminuria (urine albumin, urine creatinine, urine albumin/creatinine ratio [UACR]), total cholesterol, high density lipoprotein, very low density

Figure 1 Distribution of patients.
Mean change of urine albumin in Telmisartan group was 27.09±31.56
Mean change of urine albumin in Enalapril group was 27.09±25.70

Figure 2 Urine Albumin.
Mean change of urine creatinine in Telmisartan group was 0.94±0.4
Mean change of urine creatinine in Enalapril group was 0.83±0.26

Citation: Siva SB, Akhil D, Haripriya K, et al. Efficacy of telmisartan and enalapril in patients with diabetic nephropathy. Adv Obes Weight Manag Control. 2019;9(2):53–57. DOI: 10.15406/aowmc.2019.09.00274
lipoprotein, low density lipoprotein, and triglycerides were observed. To our knowledge, there has been one clinical study that has directly compared the effect of an angiotensin II–receptor blocker (losartan) with that of an ACE inhibitor (enalapril) in subjects with type 2 diabetes and early nephropathy.\textsuperscript{13} That short-term study indicated that both drugs reduced urinary albumin excretion; differences between the treatments were not significant. In our study Telmisartan and Enalapril therapy from baseline to visit-3 has shown a greater efficacy in both groups but enlapril group is more efficacious in decreasing the microalbuminuria levels than telmisartan group.

**Conclusion**

Both Telmisartan and Enalapril were efficacious in diabetic nephropathy patients, but Enalapril confers more reno protection when compared with Telmisartan. This study helps Clinicians in making

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure3}
\caption{Urine Creatinine. Mean change of urine albumin/creatinine ratio in Telmisartan group was 22.89±21.3. Mean change of urine albumin/creatinine ratio in Enalapril group was 9.7±3.2.}
\end{figure}

**Figure 3** Urine Creatinine.

Mean change of urine albumin/creatinine ratio in Telmisartan group was 22.89±21.3.
Mean change of urine albumin/creatinine ratio in Enalapril group was 9.7±3.2.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure4}
\caption{Urine albumin/creatinine ratio (uar). Mean change of serum creatinine in Telmisartan group was 1.0±1.17. Mean change of serum creatinine in Enalapril group was 0.09±0.34.}
\end{figure}

**Figure 4** Urine albumin/creatinine ratio (uar). Mean change of serum creatinine in Telmisartan group was 1.0±1.17. Mean change of serum creatinine in Enalapril group was 0.09±0.34.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure5}
\caption{Serum Creatinine. Mean change of systolic blood pressure in Telmisartan group was 130.64±7.6. Mean change of systolic blood pressure in Enalapril group was 134.54±9.98.}
\end{figure}

**Figure 5** Serum Creatinine. Mean change of systolic blood pressure in Telmisartan group was 130.64±7.6. Mean change of systolic blood pressure in Enalapril group was 134.54±9.98.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure6}
\caption{Systolic Blood Pressure. Mean change of diastolic blood pressure in Telmisartan group was 75.65±9.98. Mean change of diastolic blood pressure in Enalapril group was 82.5±8.94.}
\end{figure}

**Figure 6** Systolic Blood Pressure. Mean change of diastolic blood pressure in Telmisartan group was 75.65±9.98. Mean change of diastolic blood pressure in Enalapril group was 82.5±8.94.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure7}
\caption{Diastolic Blood Pressure. Mean change of fasting blood sugar in Telmisartan group was 128.29±43.07. Mean change of fasting blood sugar in Enalapril group was 122.63±30.90.}
\end{figure}

**Figure 7** Diastolic Blood Pressure. Mean change of fasting blood sugar in Telmisartan group was 128.29±43.07. Mean change of fasting blood sugar in Enalapril group was 122.63±30.90.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure8}
\caption{Fasting Blood Sugar. Mean change of post lunch blood sugar in Telmisartan group was 180.4±48.90. Mean change of post lunch blood sugar in Enalapril group was 173±59.90.}
\end{figure}

**Figure 8** Fasting Blood Sugar. Mean change of post lunch blood sugar in Telmisartan group was 180.4±48.90. Mean change of post lunch blood sugar in Enalapril group was 173±59.90.
selection of an effective drug between an ACE inhibitor and an ARB, but clinicians should consider side effects and contraindications while prescribing these drugs in diabetic nephropathy patients.

Figure 9 Post lunch blood sugar.
Mean change of HbA1C in Telmisartan group was 7.6±2.80
Mean change of HbA1C in Enalapril group was 7.19±1.89

Figure 10 HbA1C.
Mean change of total cholesterol in Telmisartan group was 138.27±27.04
Mean change of total cholesterol in Enalapril group was 137.12±35.54

Figure 11 Total cholesterol.
Mean change of low density lipoprotein in Telmisartan group was 64.29±24.4
Mean change of low density lipoprotein in Enalapril group was 70.8±26.64

Figure 12 Low Density Lipoprotein.
Mean change of very low density lipoprotein in Telmisartan group was 29.33±9.7
Mean change of very low density lipoprotein in Enalapril group was 29.5±8.11

Figure 13 Very Low Density Lipoprotein.
Mean change of high density lipoprotein in Telmisartan group was 35.20±14.7
Mean change of high density lipoprotein in Enalapril group was 31.68±6.25

Figure 14 High density lipoprotein.
Mean change of triglycerides in Telmisartan group was 135.77±40.73
Mean change of triglycerides in Enalapril group was 144.68±29.07
Efficacy of telmisartan and enalapril in patients with diabetic nephropathy

Figure 15 Triglycerides.

Acknowledgments
None.

Conflicts of interests
Author declares there is no conflict of interest.

References
1. Zinnet P, Cowie C, Ekoe JM, et al. Classification of diabetes mellitus and other categories of glucose intolerance. International Textbook of Diabetes Mellitus. 2003.

2. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2 Suppl 2):S12–154.

3. Whiting D, Guariguata L, Weil C. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94:311–321

4. Geiss LS, Li Y, Kirtland K. Increasing the prevalence of diagnosed diabetes-united states and Puerto Rico. 1995–2010. Morb Mortal Wkly Rep (MMWR). 2012;61(45):918.

5. Burrows NR. Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S continues to decline. Diabetic care. 2010;33:73–77.

6. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97:1411–1420.

7. Wienen W, Hauel N, van Meel JC, et al. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol. 1993;110(1):245–252.

8. Schmieder RE, Bakris G, Weir MR. Telmisartan in incipient and overt diabetic renal disease. Journal of nephrology. 2011;24(3):263–273.

9. Bhansali A, Bhadada SK, Kohli HS, et al. Anti-albuminuric efficacy of a combination of angiotensin converting enzyme inhibitor & angiotensin receptor blocker in type 1 DM with nephropathy. Indian J Med Res. 2010;132:42–47.

10. Barnett AH, Bain SC, Bouter P, et al. Angiotensin–receptor blockade versus converting–enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351(19):1952–1961.

11. Björck S, Mulec H, Johnsen SA, et al. selective aldosteron blockade with eplerenone reduces albuminuria in with type 2 patients diabetes. American society of nephrology. 2006;1(5):1.

12. Anthony H. Barnett, Stephen C Bain, Paul Bouter, et al., Angiotensin –receptor blockade versus converting – enzyme inhibition in type 2 diabetes and nephropathy”. N Engl J Med. 2004;51:1952–1961.

13. Lacourciere Y, Belanger A, Godin C, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney It. 2000;58:762–769.